AIM ImmunoTech Inc. 10-Q

ITEM 5: Other Information In September 2021, Ellen Lintal informed us that she intended to retire as Chief Financial Officer effective March 31, 2022 and, therefore, would not be renewing her contract. The retirement date permits her to prepare and file our next annual report on Form 10-K for the year ending December 31, 2021. Ms. Lintal has agreed to remain available to us after her retirement — on a contractual basis — to assist with future annual and quarterly filings with the SEC. ITEM 6: Exhibits (a) Exhibits 10.1 July 8, 2021 Reservation and Start-Up Agreement with hVIVO Services Limited (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10))* 10.2 September 27, 2021 Clinical Trial Agreement with hVIVO Services Limited (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10))** 31.1 Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Executive Officer.* * 31.2 Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Financial Officer.* * 32.1 Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Executive Officer.* * 32.2 Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Financial Officer.* * 39 101.INS XBRL Instance Document ** *** 101.SCH XBRL Taxonomy Extension Schema Document ** *** 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document ** *** 101.DEF XBRL Taxonomy Extension Definition Linkbase Document ** *** 101.LAB XBRL Taxonomy Extension Label Linkbase Document ** *** 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document ** *** 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed with the Securities and Exchange Commission as an exhibit to the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2021 filed August 16, 2021 and is hereby incorporated by reference. ** Filed herewith. *** Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities and Exchange Act of 1934, as amended and otherwise are not subject to liability under those sections. 40 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AIM IMMUNOTECH INC. /s/ Thomas K. Equels Thomas K. Equels, Esq. Chief Executive Officer & President /s/ Ellen M. Lintal Ellen M. Lintal Chief Financial Officer Date: November 15, 2021 41